[
  {
    "ts": null,
    "headline": "Stock Market Today: Indexes End Lower; Moderna Dives On FDA Memo; Synopsys, Nvidia Jump (Live Coverage)",
    "summary": "The Dow fell on the stock market today. Moderna skidded after an FDA memo linked Covid vaccines to deaths. A gold stock cleared an entry.",
    "url": "https://finnhub.io/api/news?id=e735727e85f4bcd0f91f10139d7648c0c233d669693ebe449d6f6a8257b0f4a3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764625105,
      "headline": "Stock Market Today: Indexes End Lower; Moderna Dives On FDA Memo; Synopsys, Nvidia Jump (Live Coverage)",
      "id": 137658735,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "The Dow fell on the stock market today. Moderna skidded after an FDA memo linked Covid vaccines to deaths. A gold stock cleared an entry.",
      "url": "https://finnhub.io/api/news?id=e735727e85f4bcd0f91f10139d7648c0c233d669693ebe449d6f6a8257b0f4a3"
    }
  },
  {
    "ts": null,
    "headline": "AMGN Up Almost 16% in a Month: Should You Buy, Sell or Hold the Stock?",
    "summary": "Amgen's nearly 16% surge follows strong Q3 results, raised sales guidance and growing momentum across key drugs and biosimilars.",
    "url": "https://finnhub.io/api/news?id=78d2fbdffc373e7d6e89b8f8320cc8da650da2e6559f9b9f047819ae4b04b2ca",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764604800,
      "headline": "AMGN Up Almost 16% in a Month: Should You Buy, Sell or Hold the Stock?",
      "id": 137658837,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen's nearly 16% surge follows strong Q3 results, raised sales guidance and growing momentum across key drugs and biosimilars.",
      "url": "https://finnhub.io/api/news?id=78d2fbdffc373e7d6e89b8f8320cc8da650da2e6559f9b9f047819ae4b04b2ca"
    }
  },
  {
    "ts": null,
    "headline": "ARWR: Multiple Data Readouts Ahead in 2026…",
    "summary": "By David Bautz, PhD NASDAQ:ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Multiple Data Readouts Ahead in 2026 Following the recent approval of REDEMPLO ® for the treatment of patients with familial chylomicronemia syndrome (FCS), Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is now a commercial-stage company and recently reported that the drug is available for patients only one week",
    "url": "https://finnhub.io/api/news?id=743332fcba984b4dc41aaff51bd7b956bb5f9e1366fcfb2f26c1fc5992ad2189",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764589680,
      "headline": "ARWR: Multiple Data Readouts Ahead in 2026…",
      "id": 137659155,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "By David Bautz, PhD NASDAQ:ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Multiple Data Readouts Ahead in 2026 Following the recent approval of REDEMPLO ® for the treatment of patients with familial chylomicronemia syndrome (FCS), Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is now a commercial-stage company and recently reported that the drug is available for patients only one week",
      "url": "https://finnhub.io/api/news?id=743332fcba984b4dc41aaff51bd7b956bb5f9e1366fcfb2f26c1fc5992ad2189"
    }
  }
]